Rabbit Anti-Human Thymocyte Globulin — Competitive Intelligence Brief

Rabbit Anti-Human Thymocyte Globulin (Rabbit Anti-Human Thymocyte Globulin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody. Area: Immunology.

phase 3 Monoclonal antibody T cells Immunology Small molecule

Target snapshot

Rabbit Anti-Human Thymocyte Globulin (Rabbit Anti-Human Thymocyte Globulin) — Dr. Claudia Bösmüller. Rabbit Anti-Human Thymocyte Globulin works by depleting T lymphocytes, thereby reducing the immune response.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rabbit Anti-Human Thymocyte Globulin TARGET	Rabbit Anti-Human Thymocyte Globulin	Dr. Claudia Bösmüller	phase 3	Monoclonal antibody	T cells
Bepreve	BEPOTASTINE	Bausch Health	marketed	Histamine-1 Receptor Antagonist	H1-receptor, mast cells	2009-01-01
CROMOLYN SODIUM	CROMOLYN SODIUM		marketed	Mast cell stabilizer	Mast cells	1982-01-01
bepotastine besilate ophthalmic solution	bepotastine besilate ophthalmic solution	Bausch & Lomb Incorporated	marketed		H1-receptor, mast cells
Placebo followed by Fisetin	Placebo followed by Fisetin	Wake Forest University Health Sciences	marketed	Senolytic agent	Multiple targets including PI3K/Akt and p38 MAPK pathways in senescent cells
Glatiramer Acetate (OL)	Glatiramer Acetate (OL)	Teva Branded Pharmaceutical Products R&D, Inc.	phase 3	Immunomodulator; disease-modifying therapy (DMT)	Myelin-reactive T cells; MHC class II molecules
Ketotifen/naphazoline	Ketotifen/naphazoline	Bausch & Lomb Incorporated	phase 3	Mast cell stabilizer / antihistamine / decongestant combination	H1 receptor, mast cells, alpha-1 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody class)

1. Pfizer · 7 drugs in this class
2. argenx · 7 drugs in this class
3. Johnson & Johnson · 2 drugs in this class
4. German CLL Study Group · 2 drugs in this class
5. Amgen · 2 drugs in this class
6. Hoffmann-La Roche · 2 drugs in this class
7. Brii Biosciences Limited · 2 drugs in this class
8. Alexion Pharmaceuticals, Inc. · 2 drugs in this class
9. Biotest · 2 drugs in this class
10. Fondazione Italiana Linfomi - ETS · 2 drugs in this class